| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
|
Gagelmann, Nico
|
|
|
9 |
10 |
p. e786-e795
|
artikel
|
| 2 |
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes
|
Pleyer, Lisa
|
|
|
9 |
10 |
p. e714-e716
|
artikel
|
| 3 |
A survey on the patient perspective on cure in multiple myeloma
|
Mohyuddin, Ghulam Rehman
|
|
|
9 |
10 |
p. e716-e719
|
artikel
|
| 4 |
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
|
Bazinet, Alexandre
|
|
|
9 |
10 |
p. e756-e765
|
artikel
|
| 5 |
Caregivers—an undervalued and underused essential
|
The Lancet Haematology,
|
|
|
9 |
10 |
p. e707
|
artikel
|
| 6 |
CD19 CAR T cells for infants and young children
|
Shalabi, Haneen
|
|
|
9 |
10 |
p. e712-e714
|
artikel
|
| 7 |
Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice
|
Malard, Florent
|
|
|
9 |
10 |
p. e776-e785
|
artikel
|
| 8 |
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
|
Taher, Ali T
|
|
|
9 |
10 |
p. e733-e744
|
artikel
|
| 9 |
Luspatercept in patients with non-transfusion dependent β-thalassaemia
|
Platzbecker, Uwe
|
|
|
9 |
10 |
p. e709-e711
|
artikel
|
| 10 |
Mitapivat for treatment of pyruvate kinase deficiency
|
Costa, Fernando F
|
|
|
9 |
10 |
p. e708-e709
|
artikel
|
| 11 |
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
|
Glenthøj, Andreas
|
|
|
9 |
10 |
p. e724-e732
|
artikel
|
| 12 |
Monika Asnani — addressing the unmet needs of sickle cell disease
|
Cavanaugh, Ray
|
|
|
9 |
10 |
p. e721
|
artikel
|
| 13 |
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
|
Cramer, Paula
|
|
|
9 |
10 |
p. e745-e755
|
artikel
|
| 14 |
Should patients with haemophilia receive gene therapy?
|
VandenDriessche, Thierry
|
|
|
9 |
10 |
p. e722-e723
|
artikel
|
| 15 |
The evolving multi-agent options for chronic lymphocytic leukaemia treatment
|
de la Serna, Javier
|
|
|
9 |
10 |
p. e711-e712
|
artikel
|
| 16 |
The underrepresented majority
|
León, Andrés Gómez-De
|
|
|
9 |
10 |
p. e720
|
artikel
|
| 17 |
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
|
Ghorashian, Sara
|
|
|
9 |
10 |
p. e766-e775
|
artikel
|
| 18 |
Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia
|
Soumerai, Jacob D
|
|
|
9 |
10 |
p. e796
|
artikel
|
Tijdschrift beschrijving